Despite the incremental technological advances in cross-sectional imaging techniques [ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI)], there is still some concern that the imaging technology available today is inadequate for appropriate prioritization for liver trans
Staging of hepatocellular carcinoma
β Scribed by Timothy M. Pawlik; Eddie K. Abdalla; Melanie Thomas; Mark S. Roh; Gregory Y. Lauwers; Dario Ribero; Ronnie T. Poon; Jacques Belghiti; David M. Nagorney; Jean-Nicolas Vauthey
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 55 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
We previously reported encouraging results of downstaging of hepatocellular carcinoma (HCC) to meet conventional T2 criteria (one lesion 2-5 cm or two to three lesionsΟ½3 cm) for orthotopic liver transplantation (OLT) in 30 patients as a test of concept. In this ongoing prospective study, we analyzed
We read with interest a paper by Kudo et al. published in a recent issue of HEPATOLOGY that compared the predictive power between Japan Integrated Staging (JIS) system and Cancer of the Liver Italian Program (CLIP) system in a large patient cohort with hepatocellular carcinoma (HCC). 1 The authors c
The Consensus Panel makes the following recommendations based on the above currently available evidence. 1. The primary staging should be clinical staging, which can be applied to all patients. The CLIP system should be the clincial staging system of choice, because it is generally applicable to mo
Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world, and the third most common cause of cancer-related death. It affects mainly patients with cirrhosis of any etiology. Patients with cirrhosis are thus usually included in surveillance plans aiming to achieve early detection